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Abstract 
Background: 
A number of studies have found associations between dysbindin (DTNBP1) polymorphisms 
and schizophrenia.  Recently we identified a DTNBP1 SNP (rs9370822) that is strongly 
associated with schizophrenia.  Individuals diagnosed with schizophrenia were nearly three 
times as likely to carry the CC genotype compared to the AA genotype.   
Methods: 
To investigate the importance of this SNP in the function of DTNBP1, a number of 
psychiatric conditions including addictive behaviours and anxiety disorders were analysed for 
association with rs9370822.   
Results: 
The DTNBP1 polymorphism was significantly associated with post-traumatic stress disorder 
(PTSD) as well as nicotine and opiate dependence but not alcohol dependence.  Individuals 
suffering PTSD were more than three times as likely to carry the CC genotype compared to 
the AA genotype.  Individuals with nicotine or opiate dependence were more than twice as 
likely to carry the CC genotype compared to the AA genotype.   
Conclusions: 
This study provides further support for the importance of DTNBP1 in psychiatric conditions 
and suggests that there is a common underlying molecular defect involving DTNBP1 that 
contributes to the development of several anxiety and addictive disorders that are generally 
recognised as separate clinical conditions.  These disorders may actually be different 
expressions of a single metabolic pathway perturbation.  As our participant numbers are 
limited our observations should be viewed with caution until they are independently 
replicated.  
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Background 
Dystrobrevin binding protein 1 (DTNBP1) is a neuronal protein that binds to alpha- and beta-
dystrobrevin in muscle and brain [1].  Association and functional studies suggest a role for 
the DTNBP1 gene in schizophrenia.  Linkage studies first identified DTNBP1 as a region of 
high schizophrenia susceptibility [2-4] and polymorphisms in DTNBP1 have since been 
identified to be associated with schizophrenia [3, 5, 6].  Biologically, DTNBP1 is a strong 
candidate for schizophrenia pathogenesis as it is thought to play a pivotal role in regulating 
the glutamatergic system [7, 8].  Glutamate hypofunction leads to increased sensory flooding 
and changes in dopamine concentration.  Hence, glutamate receptor agonist drugs are now 
used in the treatment of schizophrenia [9].  Functional studies of DTNBP1 provide further 
evidence for its role in schizophrenia aetiology.  Reduced DTNBP1 mRNA expression in 
cerebral cortex has been associated with risk haplotypes for schizophrenia [10].  Reduced 
DTNBP1 mRNA and protein expression has been found in the hippocampal formation and 
dorsolateral prefrontal cortex of schizophrenia patients [11-13].  Schizophrenia patients 
showed reduced presynaptic DTNBP1 which was related to glutamatergic alterations in 
intrinsic hippocampal formation connections [11].  More recently, it has been established that 
reductions in protein in the brains of schizophrenia patients occurred in the dysbindin-1C 
isoform but not dysbindin-1A or -1B [14].  Studies also concluded that dysbindin-1C in the 
human brain is concentrated in the synapses [14].  Tang et al. [14] concluded that decreased 
dysbindin-1C in the dorsolateral prefrontal cortex may induce NMDA receptor hypofunction 
in fast-spiking interneurons contributing to the cognitive deficits of schizophrenia.  
DTNBP1 is associated with other psychotic conditions.  Association with DTNBP1 was found 
with bipolar disorder but only in a small subgroup characterised by the complication of 
psychotic features during episodes of mood disturbance [15].  Methamphetamine psychosis is 
clinically similar to schizophrenia [16, 17] and a recent study hypothesised that DTNBP1 may 
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also be associated with substance-induced psychoses [18].  Significant associations with 
methamphetamine psychosis and DTNBP1 variation was identified in a case-control study 
[18].   
The aim of this study was to examine whether DTNBP1 variation shows genetic association 
with a range of psychiatric conditions, including schizophrenia, suggesting that changes in 
metabolism related to variations in DTNBP1 protein function underlies a common molecular 
defect in these conditions.  A polymorphism in the human dopamine D2 receptor (DRD2) 
(rs6277) has previously been found to be associated with a number of psychiatric conditions 
or traits associated with psychopathology.  The DRD2 polymorphism was first found to be 
associated with schizophrenia [19].  Since this study rs6277 has also been found to be 
associated with post-traumatic stress disorder (PTSD) [20], working memory ability [21], 
impulsivity [22] and alcohol dependence [23].  Like the DRD2 polymorphism, a common 
polymorphism in DTNBP1 may be associated with a range of psychiatric conditions.  In a 
previous study, we found a polymorphism in DTNBP1 (rs9370822) that was strongly 
associated with schizophrenia [24].  It is also well known that anxiety and addictive disorders 
are common comorbidities of schizophrenia [25, 26], so, to examine the importance of this 
DTNBP1 SNP in addictive and anxiety disorders, a number of psychiatric groups were 
genotyped for rs9370822.   
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Methods 
Subjects 
Controls: The control group consisted of 250 unrelated Caucasians (102 female and 148 
male) with a mean age of 36.8 years (s.d. ± 12.8 years).  The control group consisted mostly 
of medical and nursing staff recruited through hospitals, and university students and 
academic staff.  Formal screening for psychological disorders was not undertaken in the 
control population.  As such the controls represent an unselected control group. 
Opiate Dependence: A total of 120 unrelated Caucasian participants (50 female and 70 male) 
diagnosed as opiate dependent were recruited for this study, all of whom were being assessed 
for naltrexone treatment as outpatients of the Hospital Alcohol and Drug Services Unit of the 
Royal Brisbane and Women’s Hospital.  Participants had a mean age of 28.7 years of age.  
Approximately half of the participants were being managed on methadone prior to 
detoxification (47.2%) while the other half were on heroin (52.8%).  Those on methadone 
had a mean dose of 48.1 milligrams (s.d. 30.5), with a range between 10-165 milligrams.  The 
mean age of onset of heroin use was 22.4 years of age (s.d. 5.14), with a range between 15-43 
years.  Mean number of participant-reported detoxifications prior to this occasion was 3.5 
(s.d. 3.3), with a range between 0-16 detoxifications.  Cannabis was the most commonly 
concurrently used illicit substance reported by participants prior to treatment (52.5% reported 
use), followed by amphetamines (14.9% reported use). 
PTSD: A total of 127 unrelated male Caucasian patients diagnosed with PTSD using 
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria were recruited 
through the Greenslopes Private Hospital for the study.  All subjects were Vietnam combat 
veterans who had served in the Australian Armed Forces with a mean age of 52.3 years (s.d. 
± 6.1 years).  None were being treated with psychotropic medications.  Patients were 
excluded from the study if they had a diagnosis of psychosis, bipolar disorder, obsessive-
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compulsive disorder, or organic brain syndrome including dementia.  All subjects had 
sufficient comprehension of English and could understand the administered questionnaires.  
Patients were assessed for PTSD by a consultant psychiatrist or a senior psychiatric registrar 
using DSM-IV criteria.  Furthermore, every patient exceeded the clinical cut-off score of 94 
on the Mississippi Scale for combat-related PTSD [27].  Patient clinical history and 
demographic data including ethnic background were also obtained.  After the procedure had 
been fully explained, all participants provided written informed consent.  They were able to 
terminate their involvement at any time during the interview without prejudice.  Institutional 
ethics approval was obtained from the Greenslopes Private Hospital. 
Alcohol Dependence: A total of 231 unrelated Caucasian (47 female and 184 male) alcohol 
dependent subjects were recruited at the Royal Brisbane and Women's Hospital and the 
Princess Alexandra Hospital in Brisbane, Australia.  The mean age of the group was 42.1 
years (s.d. ± 10.8 years).  All subjects were assessed by a clinical psychologist experienced in 
drug and alcohol dependence and met DSM-IV criteria of alcohol dependence disorder.  All 
were inpatients and represented a spectrum of severity with a significant proportion (n = 65) 
of these patients being diagnosed with two or more alcohol related medical conditions such as 
pancreatitis, cirrhosis, hepatitis or peripheral neuropathy.  Alcohol dependent patients were 
excluded from the study if they had dementia, delirium, psychosis, or any other condition that 
would affect their ability to provide informed consent. 
Nicotine Dependence: A total of 147 (68 male, 79 female) unrelated Caucasians with a mean 
age of 43.3 (s.d. ± 11.1 years) were recruited for this study through hospital and media 
advertisements.  Participants were 18 years of age or older and had smoked for at least three 
years and were generally healthy despite currently smoking 15 cigarettes or more per day.  
All were motivated to reduce smoking and had the goal of eventual cessation.  However, all 
participants had at least one serious but unsuccessful attempt at quitting in the previous 24 
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months.  One hundred and thirty nine of the participants were administered the Fagerstrom 
test for Nicotine Dependence [28]. 
To minimise population stratification bias, both control and clinical subjects were all 
recruited in the Brisbane region (a city of approximately 2 million inhabitants on the East 
Coast of Australia) and all were of British or European descent. 
Ethics approval was obtained from all institutions involved and each participant gave written 
informed consent.  This study was carried out in accordance with The Code of Ethics of the 
World Medical Association (Declaration of Helsinki). 
Genotyping 
Oragene kits were used to extract DNA from saliva samples.  Samples were genotyped using 
a homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility.  The hME assay is based on the annealing of an oligonucleotide primer 
(hME primer) adjacent to the SNP of interest.  The addition of a DNA polymerase along with 
a mixture of terminator nucleotides allows extension of the hME primer through the 
polymorphic site and generates allele-specific extension products, each having a unique 
molecular mass.  The resultant masses of the extension products are then analysed by matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 
a genotype is assigned in real time.  The hME assay was performed in multiplex with up to 
36 reactions in a single well.  Genotyping failure rates varied between two and five percent. 
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Statistical Analysis 
A Pearson’s χ2 test was performed to identify statistical associations between alleles and 
genotype and schizophrenia status.  Odds ratios (OR) were also calculated.  Tests were 
performed on both genotype and allele data.  Statistical tests were performed using the 
COMPARE2 program from the WinPepi suite of epidemiology programs [29] and SPSS 
version 16.  Hardy-Weinberg equilibrium (HWE) was computed using Utility Programs for 
Analysis of Genetic Linkage [30].  The analysis of genotypes under a recessive model 
involved pooling the low-risk homozygotes and the heterozygotes and comparing frequencies 
with the high-risk homozygotes, i.e. OR > 1.  Data were not corrected for multiple testing as 
only one SNP was tested in five entirely separate case groups. 
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Results 
In order to investigate the role of the DTNBP1 SNP, rs9370822, in a range of psychiatric 
conditions, it was genotyped in 250 controls, 127 PTSD subjects, 147 nicotine dependent 
subjects, 120 opiate dependent subjects and 231 alcohol dependent subjects.  In addition to 
our previously reported association with schizophrenia, rs9370822 was found to be associated 
with PTSD, opiate dependence and nicotine dependence at the allele level but not with 
alcohol dependence (Table 1).   
At the genotype level, rs9370822 was still associated with schizophrenia, PTSD, opiate 
dependence and nicotine dependence (Table 2).  Individuals with PTSD were more than three 
times as likely to carry the CC genotype compared to the AA genotype.  In addition, they 
were almost twice as likely to be heterozygous, suggesting a partially dominant mode of 
inheritance, ie the heterozygote OR was intermediate between the associated (CC) and non-
associated (AA) genotypes (Table 2).  Individuals with nicotine or opiate dependence were 
two and a half times as likely to carry the CC genotype compared to the AA genotype. 
Examination of the genotype odds ratios suggests that, like PTSD, a partially dominant mode 
of inheritance is operating for nicotine dependence.  However, when compared to the low-
risk homozygote, the odds ratio of the other two genotypes indicated that either a very weak 
partially dominant mode of inheritance or, more likely, a C-allele-recessive pattern of 
inheritance for schizophrenia and opiate dependence was present, i.e. both the heterozygote 
OR and the OR for the low-risk homozygote were approximately one.  The rs9370822 SNP 
was found to be associated with schizophrenia and opiate dependence when analysed under a 
recessive model by pooling genotypes (schizophrenia recessive pattern of inheritance, p = 
0.0017, OR = 2.51 95% CI 1.34 to 4.74; opiate dependence recessive pattern of inheritance, p 
= 0.014, OR = 2.22 95% CI 1.10 to 4.46).   
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Alcohol dependence was not found to be associated with rs9370822 at the genotype level or 
under any inheritance model.  All sample groups were determined to be in Hardy-Weinberg 
equilibrium based on the respective genotype frequencies of each group (controls, χ2 = 0.007, 
p=0.93; PTSD, χ2 = 0.272, p=0.60; opiate dependence, χ2 = 2.11, p=0.15; nicotine 
dependence, χ2 = 0.64, p=0.42; alcohol dependence, χ2 = 0.12, p=0.73).   
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Discussion 
In order to identify a common molecular mechanism of disease etiology, DTNBP1 SNP, 
rs9370822, was chosen for analysis in a number of psychiatric conditions as we found it to be 
significantly associated with schizophrenia in a previous study [24].  To replicate our findings 
and examine the importance of this SNP in psychiatric disorders and potential brain 
functioning, we analysed a number of groups including addictive behaviours and anxiety 
disorders.  In addition to schizophrenia, analysis of rs9370822 revealed associations with 
PTSD, opiate dependence and nicotine dependence at both the allele and genotype levels.  
Alcohol dependence was not found to be associated with rs9370822 in our study but 
association with rs9370822 cannot be ruled out as we only analysed 231 alcohol dependent 
cases and the p-value was approaching significance at both the allele and genotype level 
(Tables 1 and 2).  While a strong effect of DTNBP1 was observed in four clinically distinct 
phenotypes the results should be treated with caution as there is a considerable difference in 
the gender proportions between cases and controls, for example the PTSD cohort were all 
male while 41% of controls were women.  Also, because five different diseases were 
examined it is not surprising that there are also differences with regard to age (ranging from a 
mean age of 29 years in opiate dependent cases to 52 years in Vietnam veterans with PTSD). 
Our schizophrenia study was the first to identify rs9370822 to be associated with a 
psychiatric condition [24].  The position of this SNP is likely to be a region for high 
schizophrenia susceptibility as three other SNPs (rs875462, rs760666 and rs7758659) flank 
rs9370822 and have been found to be significantly associated with schizophrenia [5, 31].  We 
also found two other flanking SNPs (rs9370823 and rs4236176) to be associated with 
schizophrenia in a recent study [24].  Although the rs9370822 SNP is intronic it is possible 
that it is a functional SNP that affects RNA splicing or gene transcription.  It could also be in 
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linkage disequilibrium with a functional SNP.  However a functional polymorphism in a 
nearby region that is associated with any psychiatric condition has yet to be identified.   
The relationship between abnormal dysbindin function and addictive and anxiety disorders is 
unclear.  Our findings may indicate that the rs9370822 polymorphism affects susceptibility to 
addictive and anxiety disorders by implication of glutamatergic neurotransmission or the 
dopamine system.  We previously identified rs9370822 to follow a recessive pattern of 
inheritance with respect to schizophrenia risk [24] which is consistent with the recessive 
inheritance of dysbindin-1 gene deletion in the mouse model of schizophrenia [32].  In this 
study we also observed that opiate dependence appeared to follow a recessive pattern of 
inheritance.  However, PTSD and nicotine dependence appeared to follow a partially 
dominant pattern.  Given this, it is possible that rs9370822 results in a reduction of DTNBP1 
function resulting in a recessive loss-of-function pattern in certain disorders, presumably 
because the loss of function from one allele is not sufficient to increase susceptibility to 
disease detectably but loss of function of both alleles does.  In other disorders a 
haploinsufficiency mechanism is operating and results in a partially dominant mode of 
inheritance, i.e. loss of function in one allele increases susceptibility to disease but not as 
much as loss of function in both alleles.   
It has also been reported that variation in DTNBP1 may affect the dopamine pathway as 
dysbindin overexpression decreases dopamine release and suppression of dysbindin 
expression increases dopamine release in the mouse in vitro [33].  A study has also found that 
dysbindin deficiency can increase the level of cell surface DRD2 and enhance DRD2 
signalling [34].   
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Conclusions 
The DTNBP1 polymorphism identified in this study is possibly involved in psychiatric 
liability not only for schizophrenia but also for addictive and anxiety disorders.  It is possible 
that DTNBP1 variation affects a common pathway involved in anxiety and addictive 
disorders.  Whether this pathway involves dopamine or glutamate signalling or both, remains 
to be elucidated.  As our participant numbers are limited our observations should be viewed 
with caution until they are independently replicated.  However, the associations are unlikely 
to occur by chance due to sample size as five separate groups were analysed (including 
schizophrenia in a previous study) and four have been found to be significantly associated 
with rs9370822.  Although this SNP is intronic, it has been found to be strongly associated 
with schizophrenia, PTSD, opiate and nicotine dependence.  Future studies may explore 
whether this SNP is functional and what effect it has on DTNBP1 functioning in the brain.   
Our findings are at odds with current knowledge as these conditions are generally regarded as 
separate clinical entities.  However, our data suggests that these conditions may be different 
phenotypic expressions of the same fundamental molecular defect in either the dopamine or 
glutamate pathways, or both.  Supporting this idea, a recent review of GWAS studies in 
schizophrenia Duan et al. [35] suggested that a pleiotropic mechanism may underlie the 
genetic overlap of schizophrenia with autism and with bipolar disorder.  
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Table 1.  Allele Association of DTNBP1 SNP rs9370822  
 
 
 
 
 
 
 
* p-value determined by Pearson’s χ2 test 
† previously published data [24] 
 
   
Sample set χ2 p-value* Odds Ratio 95% CI 
Schizophrenia† 9.883 0.002 1.61 1.19-2.17 
PTSD 12.603 0.0004 1.78 1.28-2.50 
Nicotine dependence 7.238 0.007 1.53 1.11-2.13 
Opiate Dependence 5.143 0.023 1.47 1.04-2.08 
Alcohol dependence 1.957 0.162 1.22 0.92-1.61 
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Table 2.  Genotype Association of DTNBP1 SNP rs9370822 
Sample Set Genotype Counts p-value* 
 AA (%) AC (%) CC (%)  
control 113 (47.9) 101 (42.8) 22 (9.3)  
Schizophrenia‡ 58 (37.2) 66 (42.3) 32 (20.5)    0.004    0.002† 
Odds ratio 
p-value 
1.00 
 
1.27 
0.57 
2.83 
0.002 
 
PTSD 36 (30) 62 (51.7) 22 (18.3)    0.002    0.0004† 
Odds ratio 
p-value 
1.00 1.93 
0.02 
3.14 
0.00 
 
Nicotine dependence 46 (33.8) 70 (51.5) 20 (14.7)    0.022    0.007† 
Odds ratio 
p-value 
1.00 1.70 
0.04 
2.23 
0.05 
 
Opiate Dependence 45 (39.8) 47 (41.6) 21 (18.6)    0.04    0.027† 
Odds ratio 
p-value 
1.00 1.17 
1.00 
2.40 
0.03 
 
Alcohol dependence 92 (41.63) 103 (46.6) 26 (11.76)    0.36    0.16† 
Odds ratio 
p-value 
1.00 1.25 
0.51 
1.45 
0.49 
 
* p-value determined by Pearson’s χ2 test 
† p-value determined using the extended Mantel-Haenszel test for trend 
‡ previously published data [24] 
 
 
 
 
 
